HealthQuill Novo Nordisk A/S
Novo Nordisk A/S or Novo, has partnered with UNICEF to expand their global partnership for four years to fight childhood overweight and obesity, and the Danish company has committed $18 million until 2030.
Drugs Health Medical

Novo-UNICEF extends pact to fight child obesity, Novo to pump in $18m

HQ Team September 23, 2026: Novo Nordisk A/S or Novo, has partnered with UNICEF to expand their global partnership for four years to.

Read More
Danish drugmaker Novo Nordisk’s investigational drug, CagriSema, has achieved an estimated average weight loss of 12.4% in diabetic patients during an end-stage trial, better than rival Eli Lilly’s drug.
Health Pharma Research

Novo Nordisk’s test drug outperforms rival Lilly’s in diabetic patients

HQ Team September 21, 2026: Danish drugmaker Novo Nordisk’s investigational drug, CagriSema, has achieved an estimated average weight loss of 12.4% in diabetic.

Read More
Novo Nordisk A/S and United Laboratories International Holdings Limited (TUL) mid-stage trials, held in China, helped in reducing average blood sugar levels by up to 2.16% in diabetic patients and trimmed weight by almost 10%, according to a statement.
Drugs Health Pharma

Novo, United’s trial drug cuts sugar levels by 2.16%, weight loss of 9.8%

HQ Team March 25, 2026: Novo Nordisk A/S and United Laboratories International Holdings Limited (TUL) mid-stage trials, held in China, helped in reducing.

Read More
Novo Nordisk will acquire US-based Akero Therapeutics, Inc. for $5.2 billion to pocket an experimental drug in end-stage trials to treat liver disease, the company announced.
Drugs Health Pharma

Novo to buy Akero for $5.2 billion, to pocket trial liver disease drug

Novo Nordisk will acquire US-based Akero Therapeutics, Inc. for $5.2 billion to pocket an experimental drug in end-stage trials to treat liver disease,.

Read More
Novo Nordisk A/S has sought approval from the European Medicines Agency for a higher dose of its weight-loss drug Wegovy, after trial data showed a third of participants losing 25% of their body weight.
Drugs Health Pharma

Novo Nordisk seeks EU nod for higher dose of its weight-loss drug Wegovy

HQ Team July 8, 2025: Novo Nordisk A/S has sought approval from the European Medicines Agency for a higher dose of its weight-loss.

Read More
Danish drugmaker Novo Nordisk will terminate its agreement with a US-based telehealth company, Hims & Hers Health Inc., to sell its weight-loss drug, Wegovy.
Drugs Health Medical

Novo terminates agreement with Hims & Hers to sell weight-loss drug

HQ Team June 23, 2025: Danish drugmaker Novo Nordisk will terminate its agreement with a US-based telehealth company, Hims & Hers Health Inc.,.

Read More
Novo Nordisk’s experimental weight loss medicine amycretin helped overweight and obese adults lose up to 24% of their weight in a small study, according to a company statement.
Drugs Health Pharma

Novo Nordisk’s amycretin drug helps obese adults lose 24% weight

HQ Team June 21, 2025: Novo Nordisk’s experimental weight loss medicine amycretin helped overweight and obese adults lose up to 24% of their.

Read More
Denmark’s Novo Nordisk will advance its experimental drug amycretin, in both injection and oral forms, into end-stage trials in weight management based on completed clinical studies, according to a company statement.
Drugs Health Pharma

Novo Nordisk’s obesity drug to begin end-stage trials in early 2026

HQ Team July 13, 2025: Denmark’s Novo Nordisk A/S will advance its experimental drug amycretin, in both injection and oral forms, into end-stage.

Read More
Denmark’s Novo Nordisk A/S and US-based Deep Apple Therapeutics Inc. signed an $812 million agreement to develop an oral small molecule targeting cardiometabolic diseases, such as obesity.
Climate Health Research

Novo Nordisk in $812m pact with Deep Apple for oral small molecule

HQ Team June 11, 2025: Denmark’s Novo Nordisk A/S and US-based Deep Apple Therapeutics Inc. signed an $812 million agreement to develop an.

Read More